EA202091524A1 - Ингибиторы рецептора, активируемого протеазой 2 - Google Patents

Ингибиторы рецептора, активируемого протеазой 2

Info

Publication number
EA202091524A1
EA202091524A1 EA202091524A EA202091524A EA202091524A1 EA 202091524 A1 EA202091524 A1 EA 202091524A1 EA 202091524 A EA202091524 A EA 202091524A EA 202091524 A EA202091524 A EA 202091524A EA 202091524 A1 EA202091524 A1 EA 202091524A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protease
inhibitors
activated receptor
par
present
Prior art date
Application number
EA202091524A
Other languages
English (en)
Inventor
Луиджи Аурелио
Найджел Баннет
Бернард Люк Флинн
Ле Джианг
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017905084A external-priority patent/AU2017905084A0/en
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA202091524A1 publication Critical patent/EA202091524A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение в основном относится к соединениям, способным ингибировать рецептор, активируемый протеазой 2 (PAR), и их применению. Более конкретно, настоящее изобретение относится к ингибиторам PAR, их получению и применению при лечении заболеваний и расстройств, опосредованных передачей сигнала PAR.
EA202091524A 2017-12-20 2018-12-19 Ингибиторы рецептора, активируемого протеазой 2 EA202091524A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017905084A AU2017905084A0 (en) 2017-12-20 Inhibitors of Protease Activated Receptor-2
PCT/JP2018/047988 WO2019124567A1 (en) 2017-12-20 2018-12-19 Inhibitors of protease activated receptor-2

Publications (1)

Publication Number Publication Date
EA202091524A1 true EA202091524A1 (ru) 2020-09-16

Family

ID=65244543

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091524A EA202091524A1 (ru) 2017-12-20 2018-12-19 Ингибиторы рецептора, активируемого протеазой 2

Country Status (10)

Country Link
US (1) US20200383985A1 (ru)
EP (1) EP3727386A1 (ru)
JP (1) JP2021508692A (ru)
CN (1) CN111698991A (ru)
AU (1) AU2018388104A1 (ru)
BR (1) BR112020012589A2 (ru)
CA (1) CA3086458A1 (ru)
EA (1) EA202091524A1 (ru)
MX (1) MX2020006533A (ru)
WO (1) WO2019124567A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516734A (ja) * 2016-05-20 2019-06-20 武田薬品工業株式会社 疼痛の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE442865T1 (de) * 2004-04-08 2009-10-15 Jado Technologies Gmbh Dreigeteilte konjugate mit einer struktur, die mit zellmembran-rafts interagieren und ihre verwendung
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
CA2924690A1 (en) * 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
JP2019516734A (ja) * 2016-05-20 2019-06-20 武田薬品工業株式会社 疼痛の治療

Also Published As

Publication number Publication date
WO2019124567A1 (en) 2019-06-27
US20200383985A1 (en) 2020-12-10
BR112020012589A2 (pt) 2020-11-24
MX2020006533A (es) 2020-12-09
JP2021508692A (ja) 2021-03-11
CN111698991A (zh) 2020-09-22
AU2018388104A1 (en) 2020-07-09
EP3727386A1 (en) 2020-10-28
CA3086458A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
DOP2018000010A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201890111A1 (ru) Замещенные производные оксопиридина
EA201790806A1 (ru) Иммунорегулирующие средства
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790992A1 (ru) Иммунорегуляторные агенты
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201990400A1 (ru) Соединения и композиции и их применение
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202191115A1 (ru) Новые пиридазины
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины